Downstream Bioprocessing 2021

Current trends in AAV downstream bioprocessing and future considerations

Cell & Gene Therapy Insights 2021; 7(11), 1521–1526


Published: 6 December 2021
Michael Mercaldi

Michael MercaldI is the Senior Director of Downstream Process Development at Homology Medicines. He is responsible for leading the development of Homology’s purification and drug product manufacturing processes for their gene therapy and gene editing programs. He has held positions in process development throughout his career at MedImmune/AstraZeneca, Merrimack Pharmaceuticals and Codiak Biosciences before joining Homology. He holds a BS in Chemical Engineering from the Rensselaer Polytechnic Institute and a PhD in Biochemical Engineering from Tufts University.